On October 17, 2025, Yang Yupeng, a leader of the Haikou International Investment Promotion Bureau, visited Zhejiang Tianyuan Biotechnology Co., Ltd. for inspection and guidance. General Manager Jiao Mingming and Group Executive Director Zhu Youwu led the team in warmly receiving the guest.

      Accompanied by company representatives, Yang Yupeng toured the company's technology exhibition hall, gaining an in-depth understanding of Tianyuan Bio's development history, business layout, and innovative achievements in the field of cell therapy. The rich content and diverse display facilities in the exhibition hall vividly demonstrated the company's profound expertise in the biomedicine sector. Subsequently, Yang Yupeng visited the laboratories, praising their high-standard construction and advanced research equipment.

      During the subsequent visit to the Tianhao Holding Group headquarters, Executive Director Zhu provided a detailed introduction to the company's overall strengths and three major industries, covering aspects such as development history, organizational structure, business scope, and future plans, highlighting Tianyuan Bio's leading position in the industry. At the follow-up exchange meeting, Dr. Chen Junjie, the company's Technical Director and a postdoctoral fellow from Harvard Medical School, presented the company's scientific research progress, elaborating on the achievements in iPS cell technology and the unique advantages of cell culture. He noted that the company demonstrates strong technological innovation capabilities in areas such as iPS cell induction differentiation and optimization of cell culture conditions.

      Chairman Huang Bisheng stated that the company would take this inspection as an opportunity to further strengthen communication and collaboration with the Haikou International Investment Promotion Bureau and actively explore investment and development opportunities in Hainan. General Manager Jiao Mingming expressed that Tianyuan Bio would fully leverage its technological advantages and industrial experience to contribute actively to the development of Hainan's health industry.

     Yang Yupeng affirmed Tianyuan Bio's scientific research capabilities and developmental achievements. He remarked that Tianyuan Bio's technological strength in the field of bio-health is impressive, particularly in the transformation of scientific research achievements and industrial applications. This inspection has laid a solid foundation for future collaboration between the two parties, facilitating Tianyuan Bio's industrial establishment in Hainan and injecting new vitality into the development of Hainan's biomedicine industry.

     Zhejiang Tianyuan Biotechnology Co., Ltd., founded in 2017, is a national high-tech enterprise dedicated to cell research, development, production, operation, and service. It possesses valuable resource banks, including an HLA Umbilical Cord Matching Library, iPS Seed Cell Bank, and Cancer Cell Bank. The company is the drafting unit for the National Health Commission's association standard for immune function assessment methods. In collaboration with the National Health Commission's Research Institute, it has established a Joint Laboratory for Metabolic Immunity Monitoring. Additionally, it serves as the Ningbo Storage Center for the National Stem Cell Transformation Resource Bank and the Achievement Transformation Center for the National Health Commission's Research Institute, among other key research and service platforms.